Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RD06-04 in Refractory IIM and AAV
NCT06986018Phase 1Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Jun 2025
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RD06-04 in idiopathic inflammatory myopathies (IIM) and Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), sponsored by Peking University People's Hospital. Primary endpoint: Adverse Events (TEAE, SAE, AESI) up to 2 years. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
RD06-04
03
Conditions
idiopathic inflammatory myopathies (IIM)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT06986018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06986018.